| Outcome Measures: |
Primary: WP1: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test, Lag time, maximum absorbance, time to maximum absorbance and clot lysis time, At baseline|WP1: Fibrin permeation analysis using validated test, Permeation constant (Ks), At baseline|WP1: Low density lipoprotein fractions, Measure of low density lipoprotein subclass fractions, At baseline|WP1: Oxidised low density lipoprotein, Measure of oxidised low density lipoprotein, At baseline|WP2: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test, Lag time, maximum absorbance, time to maximum absorbance and clot lysis time, At baseline and after 6 weeks of statin therapy|WP2: Fibrin permeation analysis using validated test, Permeation constant (Ks), At baseline and after 6 weeks of statin|WP2: Low density lipoprotein fractions, Measure of low density lipoprotein subclass fractions, At baseline and after 6 weeks of statin|WP2: Oxidised low density lipoprotein, Measure of oxidised low density lipoprotein, At baseline and after 6 weeks of statin | Secondary: WP1: Scanning electron microscopy, Qualitative assessment of fibril indices, At baseline
|
